Trial Outcomes & Findings for Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study (NCT NCT05530356)
NCT ID: NCT05530356
Last Updated: 2026-08-24
Results Overview
Glomerular filtration rate measured by iohexol clearance
COMPLETED
57 participants
One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening
2026-08-24
Participant Flow
Most participants will be re-recruited from the parent Renal-HEIR study (COMIRB #16-1752), who consented to be contacted for future research. New participants will also be recruited via the Lifestyle Medicine 2 clinic at Children's Hospital Colorado, by email, phone, and during clinical visits.
Participant milestones
| Measure |
Lean Control
Participants with BMI between 5th and 85th percentile, no T2D
|
Obese Control
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Overall Study
STARTED
|
9
|
15
|
33
|
|
Overall Study
COMPLETED
|
9
|
15
|
33
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Baseline characteristics by cohort
| Measure |
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
Total
n=57 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
19 Years
STANDARD_DEVIATION 2 • n=1541 Participants
|
21 Years
STANDARD_DEVIATION 4 • n=1121 Participants
|
34 Years
STANDARD_DEVIATION 19 • n=2662 Participants
|
28 Years
STANDARD_DEVIATION 16 • n=113 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=1541 Participants
|
5 Participants
n=1121 Participants
|
22 Participants
n=2662 Participants
|
29 Participants
n=113 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=1541 Participants
|
10 Participants
n=1121 Participants
|
11 Participants
n=2662 Participants
|
28 Participants
n=113 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
0 Participants
n=2662 Participants
|
0 Participants
n=113 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
2 Participants
n=2662 Participants
|
2 Participants
n=113 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
0 Participants
n=2662 Participants
|
0 Participants
n=113 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
5 Participants
n=2662 Participants
|
5 Participants
n=113 Participants
|
|
Race (NIH/OMB)
White
|
9 Participants
n=1541 Participants
|
15 Participants
n=1121 Participants
|
25 Participants
n=2662 Participants
|
49 Participants
n=113 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
0 Participants
n=2662 Participants
|
0 Participants
n=113 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
1 Participants
n=2662 Participants
|
1 Participants
n=113 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=1541 Participants
|
11 Participants
n=1121 Participants
|
18 Participants
n=2662 Participants
|
31 Participants
n=113 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
7 Participants
n=1541 Participants
|
4 Participants
n=1121 Participants
|
15 Participants
n=2662 Participants
|
26 Participants
n=113 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=1541 Participants
|
0 Participants
n=1121 Participants
|
0 Participants
n=2662 Participants
|
0 Participants
n=113 Participants
|
|
Glomerular filtration rate
|
135 mL/min/1.73m^2
STANDARD_DEVIATION 20 • n=1541 Participants
|
147 mL/min/1.73m^2
STANDARD_DEVIATION 30 • n=1121 Participants
|
149 mL/min/1.73m^2
STANDARD_DEVIATION 32 • n=2662 Participants
|
146 mL/min/1.73m^2
STANDARD_DEVIATION 29 • n=113 Participants
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningGlomerular filtration rate measured by iohexol clearance
Outcome measures
| Measure |
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Glomerular Filtration Rate
|
147 mL/min/1.73m^2
Standard Deviation 30
|
135 mL/min/1.73m^2
Standard Deviation 20
|
149 mL/min/1.73m^2
Standard Deviation 32
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningEffective renal plasma flow measured by PAH clearance
Outcome measures
| Measure |
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Effective Renal Plasma Flow (ERPF)
|
737 mL/min/1.73m^2
Standard Deviation 129
|
666 mL/min/1.73m^2
Standard Deviation 113
|
753 mL/min/1.73m^2
Standard Deviation 168
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningBOLD-MRI uses the specific paramagnetic properties of deoxyhemoglobin to assess renal tissue oxygenation. Its outcome measure is the so-called R2\* value, which varies inversely with local oxygenation. This apparent relaxation rate R2\* (or decay rate, defined as 1/T2\* and expressed as per second) is measured voxel by voxel in each kidney by BOLD-MRI. The R2\* value of each voxel is influenced by microscopic inhomogeneities in the static magnetic field, largely due to the effect of deoxyhemoglobin. As such, the decay rate R2\* in a voxel will be enhanced when the local deoxyhemoglobin concentration is increased. Hence, assuming that blood pO2 is in equilibrium with tissue pO2, low R2\* values indicate high tissue oxygenation, while high R2\* values indicate low tissue oxygenation.
Outcome measures
| Measure |
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Renal Oxygen Availability
|
17.9 1/s
Standard Deviation 1.1
|
18.9 1/s
Standard Deviation 1.6
|
18.8 1/s
Standard Deviation 1.8
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningArterial spin labeling (ASL) uses magnetically labeled arterial blood water as an endogenous tracer to assess renal perfusion. Its outcome measure is renal blood flow (RBF), expressed in mL/min/100 g of tissue. In ASL, inflowing arterial blood is magnetically tagged by inverting the longitudinal magnetization of water protons proximal to the imaging plane. After a defined post-labeling delay allowing labeled blood to flow into the tissue, a labeled image is acquired and subtracted from a control image obtained without labeling. The resulting difference signal, measured voxel by voxel in each kidney, is proportional to the labeled blood water delivered during the delay. As such, the difference signal in a voxel will be enhanced when local blood delivery is increased. Hence, after quantification using tissue and blood relaxation parameters, high perfusion values indicate high renal blood flow, while low perfusion values indicate reduced renal blood flow.
Outcome measures
| Measure |
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Renal Perfusion
|
242.1 ml/min/100gm
Standard Deviation 48.8
|
193.9 ml/min/100gm
Standard Deviation 35.9
|
205.0 ml/min/100gm
Standard Deviation 41.0
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningC-11 Acetate tracer uptake measured by PET Scan (K1)
Outcome measures
| Measure |
Obese Control
n=21 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=10 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
C-11 Acetate Tracer Uptake
|
1.100 mL/min/mL
Standard Deviation 0.222
|
1.298 mL/min/mL
Standard Deviation 0.256
|
—
|
PRIMARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningPositron emission tomography (PET) with C-11 acetate is used to assess renal oxidative metabolism. Its outcome measure is the cortical clearance rate constant k2, expressed per minute (min\^-1). Following intravenous injection, C-11 acetate is taken up by renal tissue and converted to acetyl-CoA, which enters the tricarboxylic acid (TCA) cycle and is oxidized to C-11 CO2. The washout of C-11 activity from the tissue, modeled region by region in the renal cortex, reflects the rate of this oxidative process. The clearance rate constant k2, derived from kinetic modeling of the tissue time-activity curve, will be enhanced when oxidative metabolism and TCA cycle flux are increased. Hence, assuming tracer washout is in proportion to mitochondrial oxidation, high cortical k2 values indicate high renal oxidative metabolism, while low cortical k2 values indicate reduced renal oxidative metabolism.
Outcome measures
| Measure |
Obese Control
n=21 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=10 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Renal Oxidative Metabolism
|
0.221 1/min
Standard Deviation 0.023
|
0.218 1/min
Standard Deviation 0.055
|
—
|
SECONDARY outcome
Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screeningPWV between carotid and femoral artery
Outcome measures
| Measure |
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
|
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
Pulse Wave Velocity
|
6.2 m/s
Standard Deviation 1.8
|
5.3 m/s
Standard Deviation 0.8
|
5.5 m/s
Standard Deviation 1.3
|
Adverse Events
Lean Control
Obese Control
Type 2 Diabetes
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Lean Control
n=9 participants at risk
Participants with BMI between 5th and 85th percentile, no T2D
|
Obese Control
n=15 participants at risk
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
|
Type 2 Diabetes
n=33 participants at risk
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
|
|---|---|---|---|
|
General disorders
Allergic reaction to Dextran
|
0.00%
0/9 • From enrollment until the end of study participation, an average of 1 month
|
6.7%
1/15 • From enrollment until the end of study participation, an average of 1 month
|
6.1%
2/33 • From enrollment until the end of study participation, an average of 1 month
|
Additional Information
Petter Bjornstad, MD
University of Washington; University of Colorado Anschutz Medical Campus
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place